Mohan Bala
Corporate Officer/Principal chez MERSANA THERAPEUTICS, INC.
Fortune : 62 953 $ au 31/03/2024
Profil
Mohan Bala's career history includes current and former positions as well as education.
Currently, Dr. Bala is the Chief Development Officer & Senior Vice President at Mersana Therapeutics, Inc. Prior to this, Dr. Bala held the position of Chief Operating Officer at Constellation Pharmaceuticals, Inc. and Vice President of Lead Development Program at Tesaro, Inc. Dr. Bala's education includes an MBA and a doctorate from The University of Chicago.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 16/01/2024 | 14 052 ( 0,01% ) | 62 953 $ | 31/03/2024 |
Postes actifs de Mohan Bala
| Sociétés | Poste | Début |
|---|---|---|
| MERSANA THERAPEUTICS, INC. | Corporate Officer/Principal | 25/10/2021 |
Anciens postes connus de Mohan Bala
| Sociétés | Poste | Fin |
|---|---|---|
| TESARO INC | Corporate Officer/Principal | - |
| CONSTELLATION PHARMACEUTICALS, INC. | Chief Operating Officer | - |
Formation de Mohan Bala
| The University of Chicago | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MERSANA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Tesaro, Inc.
 Tesaro, Inc. Pharmaceuticals: MajorHealth Technology TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. The firm offers Niraparib products. The company was founded by Leon Oliver Moulder, Jr., Mary Lynne Hedley, and Richard J. Rodgers on March 26, 2010 and is headquartered in Waltham, MA. | Health Technology |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
